StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Strong revenue growth and upward revisions in guidance typically boost stock prices, as seen in previous growth cycles.
What happened, with direct paths to the underlying reporting
iRhythm reported Q1 2025 revenue of $158.7 million, exceeding estimates. Adjusted EPS loss narrowed to 95 cents, outperforming consensus estimates. Launch of Zio ECG system in Japan enhances international growth prospects. Wells Fargo and Baird raise price targets, indicating positive market sentiment. iRhythm projects 2025 sales guidance of $690-$700 million, above previous estimates.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.